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Sever  lower  gastro-intestinal  bleeding  by CMV  in  a kidney
transplant with  low-dose  immunosuppression
Hemorragia  digestiva  baja  masiva  por  citomegalovirus  en  un
trasplantado  renal  con  bajas  dosis  de  inmunosupresiónn o
g may be observed. B) Histology image with H&E 400×.Dear Editor,
Cytomegalovirus (CMV) is an opportunistic virus that affects
the majority of immunocompromised patients, including
transplant recipients.1 The infection is generally caused by
reactivation of a strain in the recipient in a latent state
and, more  rarely, by infection from an exogenous strain. The
period of greatest risk for presenting a CMV  infection is dur-
ing the ﬁrst 6 months post-transplant. CMV  infection is rare
starting from the sixth month.2 Since the introduction of
new immunosuppressive agents, especially mycophenolate
mofetil, an increase in the incidence of CMV  infection has
been reported.3 However, only exceptionally does a CMV infec-
tion start as a serious complication, especially once the ﬁrst
6 months have passed since the transplant.1 We present the
case of a kidney transplant recipient with a long clinical course
with low doses of immunosuppressants who developed a
severe intestinal disease due to CMV  that required emergency
surgery.
Fig. 1 – (A) Intra-operative image of the resected specimen. A
intestine and the ulceration that is the source of the bleedin
Cytomegalic inclusions (arrows) in the interior of the mucus-dep
 Please cite this article as: Ríos A, Ruiz J, Rodríguez JM, Parrilla P. Hem
trasplantado renal con bajas dosis de inmunosupresión. Nefrologia. 20pening has been made in the resected loop of small
A 65-year-old woman with hypertension and type 2
diabetes who had received a kidney transplant 12 years ear-
lier, due to polycystic kidney disease, currently with low
doses of immunosuppression (ciclosporin 75 mg/12 h and
mycophenolate mofetil 50 mg/12 h). She visited the emer-
gency department owing to abdominal pain for the past
48 h, located in the mesogastrium and associated with vomi-
ting. Laboratory testing revealed a haemoglobin level of 6 g/dl
and no signs of gastrointestinal bleeding. An upper gastroin-
testinal endoscopy was normal, and a lower gastrointestinal
endoscopy showed multiple superﬁcial ulcers with signs of
bleeding in the terminal ileum and ascending colon. A biopsy
reported positive immunostaining for CMV.  A PCR for CMV
was requested and more  than 10,000 copies were obtained,
and so intravenous treatment was started with ganciclovir and
immunoglobulin. At 48 h she had severe lower gastrointestinal
bleeding that required transfusion of 6 packed red blood cell
units. She underwent an arteriogram of both mesenteric arter-
ies, which did not reveal the bleeding point. A colonoscopyleted intestinal cells.
orragia digestiva baja masiva por citomegalovirus en un
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howed that the previously detected ulcers had not improved
nd revealed a penetrating ulcer in the ileum with active
leeding, which was treated with endoscopic sclerosis. At
2 h the patient had a new episode of severe gastrointestinal
leeding, and so she underwent a resection of the affected
leum and the caecum. The surgical specimen showed multi-
le superﬁcial ulcers and an ulcer with a diameter of around
 cm that reached the serosa (Fig. 1A). The deﬁnitive diagnosis
as ulcerative enteritis due to CMV  (Fig. 1B). Her postoperative
ourse was favourable and, currently, at 3 years from her signs
nd symptoms, she has had no recurrence of CMV infection.
CMV  infection represents one of the most common oppor-
unistic infectious diseases after a kidney transplant, and
eads to an increase in the recipient’s morbidity and mortality.
t affects 60–80% of patients, 25–50% of whom develop clinical
isease.1,2 Symptomatic CMV  infection in the gastrointestinal
ract occurs in 5–10% of patients who receive kidney trans-
lants, and may affect the patient from the oesophagus to the
olon. Ulcers occur because CMV  causes vasculitis in the gas-
rointestinal tract, which may cause gastrointestinal bleeding
nd even intestinal perforation.4 However, late disease due
o CMV  (after 6 months have passed since the transplant) is
ncommon, especially if there is no increase in immunosup-
ressive treatment due to late acute rejection.4,5
Different studies, including some multi-centre studies,
ave shown that the use of mycophenolate mofetil decreases
he incidence of episodes of acute rejection; however, it seems
o increase the frequency and severity of CMV  infection,3,6 as
as observed in our patient. Cornelis et al.3 indicated that,
lthough it does not bring about an increase in primary CMV
nfection, it does cause an increase in development of dis-
ase due to CMV.  Our case was unique with respect to what
as been reported by several authors owing to the aggressive-
ess of the intestinal involvement despite the low doses of
mmunosuppression and the antiviral treatment started.7–10
The treatment of choice in these cases of late CMV infection
s the use of speciﬁc antiviral agents, which in the majority
f cases is effective.1,8 Colonoscopy is a good diagnostic and
herapeutic method in patients in whom a bleeding point is
ocated. In our case, the lesion was located properly, but the
reatment was not effective. Therapy with embolization using
nterventionist radiology may be used in these cases of mas-
ive bleeding; however, a ﬂow rate of 0.5 to 1 ml/min is required
o show bleeding, and this sometimes brings about a diag-
ostic problem owing to the intermittent nature of episodes
f gastrointestinal bleeding, as occurred in our case. Surgery
s reserved for cases in which all the above fails, and its
ajor problem is locating the bleeding point, as a segmental
esection, as in our case, is not the same as a massive intesti-
al resection. The mortality rate of surgery ranges between
0% and 55%.1 In our case, a segmental resection fostered the
atient’s good clinical course.
In conclusion, late intestinal CMV  infection should be sus-
ected in transplant recipients treated with mycophenolate
ho  start with latent gastrointestinal signs and symptoms.
urgery is the last therapeutic step, and locating the bleeding
oint is essential for managing signs and symptoms.(4):444–463 455
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